您当前所在的位置:首页 > 产品中心 > 产品信息
Deuterated Atazanivir-D3-3_分子结构_CAS_1092540-52-7)
点击图片或这里关闭

Deuterated Atazanivir-D3-3

产品号 S3011 公司名称 Selleck Chemicals
CAS号 1092540-52-7 公司网站 http://www.selleckchem.com
分子式 C38H52N6O7 电 话 (877) 796-6397
分子量 704.85548 传 真 (832) 582-8590
纯 度 电子邮件 sales@selleckchem.com
保 存 -20°C Chembase数据库ID: 73297

产品价格信息

请登录

产品别名

标题
Deuterated Atazanivir-D3-3
IUPAC标准名
methyl N-[(1S)-1-{N'-[(2S,3S)-2-hydroxy-3-[(2S)-2-[(methoxycarbonyl)amino]-3,3-bis(2H3)methyl(4,4,4-2H3)butanamido]-4-phenylbutyl]-N'-{[4-(pyridin-2-yl)phenyl]methyl}hydrazinecarbonyl}-2,2-bis(2H3)methyl(3,3,3-2H3)propyl]carbamate
IUPAC传统名
methyl N-[(1S)-1-{N'-[(2S,3S)-2-hydroxy-3-[(2S)-2-[(methoxycarbonyl)amino]-3,3-bis(2H3)methyl(4,4,4-2H3)butanamido]-4-phenylbutyl]-N'-{[4-(pyridin-2-yl)phenyl]methyl}hydrazinecarbonyl}-2,2-bis(2H3)methyl(3,3,3-2H3)propyl]carbamate

产品登记号

CAS号 1092540-52-7

产品性质

保存条件 -20°C

产品详细信息

详细说明 (English)
Research Area
Description Infection
Biological Activity
Description Atazanivir-D3-3 is a azapeptide derivative and inhibits HIV protease.
Targets HIV protease
IC50
In Vitro Atazanivir-D3-3 is an azapeptide derivative and a HIV protease inhibitor. Atazanivir-D3-3 is a deuterium-containing agent with ameliorated ADME properties. [1] Atazanivir-D3-3 displays a significantly longer half life, at almost 46% than atazanavir when co-dosed in chimps. Atazanavir sulfate prevents the formation of mature HIV virions in HIV-1 infected cells by selectively inhibiting the virus-specific processing of certain polyproteins (viral Gag and Gag-Pol). Atazanavir sulfate is currently approved for the treatment of HIV infection.[1] Atazanavir is contraindicated for co-administration with medicines that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. Due to inhibitory effects of atazanavir on CYP3A, CYP2C8, and UGTIAl, caution is advised when prescribing. Common adverse events associated with atazanavir include hyperbilirubinemia, rash, nausea, headache, mid jaundice/sclcral icterus. [1]
In Vivo
Clinical Trials
Features
References
[1] Harbeson, S.L., et al. Eur. Pat. Appl. 2008, 59 pp. EP 2003120 A1 20081217.